Pharmaceutical

Proposal to protect abortion patients’ records faces pu...

Data sharing systems that automatically transmit patients’ electronic health rec...

Mexico’s activist ‘companion networks’ quietly provide ...

Mexican activist groups have been quietly sending abortion pills across the bord...

STAT+: ‘Learning each other’s language’: FDA, patent of...

Patent reform advocates say closer collaboration between the FDA and PTO could m...

Opinion: Having a child with complex medical needs is h...

Having a child with complex medical needs is hard enough. Navigating the health ...

STAT+: Sanofi says it has 12 blockbusters in its back p...

Sanofi says that it is currently developing 12 experimental medicines it believe...

STAT+: To lower drug prices, White House takes new aim ...

Breaking: White House to endorse controversial patent policy to lower drug prices.

STAT+: AbbVie purchases neuroscience developer Cerevel ...

Abbvie announced Wednesday that it will purchase Cerevel Therapeutics and its pi...

New England Journal of Medicine reckons with its racist...

In the 19th century, journal authors routinely used racist and dehumanizing lang...

STAT+: Stephen Hemsley, UnitedHealth Group board chair,...

Stephen Hemsley, the board chair and former CEO of UnitedHealth Group, has sold ...

Most drugmakers have so far ignored looming FTC deadlin...

Only one company has responded to an FTC demand for several drugmakers to delist...

STAT+: Biden proposal targeting pharma patents spurs in...

The Biden administration's assertion of its authority to exercise "march-in" rig...

LY-3885125 by Eli Lilly and Co for Dyslipidemia: Likeli...

LY-3885125 is under clinical development by Eli Lilly and Co and currently in Ph...

Tislelizumab by BeiGene for Gastric Cancer: Likelihood ...

Tislelizumab is under clinical development by BeiGene and currently in Phase III...

IGM jettisons workforce and blood cancer programme to r...

IGM Biosciences plans to axe 22% of its workforce, becoming the latest company ...

Tislelizumab by BeiGene for Esophageal Squamous Cell Ca...

Tislelizumab is under clinical development by BeiGene and currently in Pre-Regis...

Tislelizumab by BeiGene for Gastroesophageal (GE) Junct...

Tislelizumab is under clinical development by BeiGene and currently in Phase III...